• In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), triggering the start of IND-enabling studies for future clinical trials.
• This progress adds an RNA-based approach to Madrigal’s largely Rezdiffra-focused pipeline, potentially broadening its toolkit for addressing a widespread liver disease with significant unmet medical need.
• We’ll now examine how adding an siRNA MASH candidate to Madrigal’s pipeline might influence its largely Rezdiffra-centric investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Madrigal Pharmaceuticals Investment Narrative Recap

Madrigal is largely a one-drug story built around Rezdiffra, so the near term still turns on execution in MASH and ongoing outcomes data. The new siRNA milestone with Suzhou Ribo modestly broadens the pipeline but does not change that the key catalyst remains Rezdiffra’s clinical and commercial progress, while heavy R&D and SG&A spending and continued losses are the biggest near term business risks.

Among recent developments, Madrigal’s inclusion in the Russell 1000 and Russell 1000 Growth indices in late June 2026 stands out. This index migration reflects its larger market footprint and can influence trading volumes and ownership mix, which matters as investors weigh Rezdiffra’s upcoming data and the early, higher risk siRNA program that has just entered IND-enabling studies.

Yet investors should also recognize the risk that, even with new RNA assets, Madrigal’s dependence on Rezdiffra leaves them exposed if...

Madrigal Pharmaceuticals' narrative projects $3.2 billion revenue and $935.6 million earnings by 2029. This requires 42.0% yearly revenue growth and about a $1.25 billion earnings increase from -$309.4 million today.

Uncover how Madrigal Pharmaceuticals' forecasts yield a $678.71 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Before this siRNA news, the most bullish analysts were assuming Madrigal could reach about US$3.6 billion in revenue and US$1.5 billion in earnings by 2028, a far more optimistic path than the baseline view. You should expect those optimistic and more cautious narratives to evolve as Rezdiffra matures and the new RNA program begins to generate its own data.

Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 13% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.